Hoth Therapeutics, Inc. - HOTH STOCK NEWS

Hoth Therapeutics, Inc. (NASDAQ: HOTH) has partnered with Worldwide Clinical Trials for a Phase 2a dose-ranging clinical trial of HT-001. This trial aims to assess the efficacy and safety of HT-001 in treating cutaneous toxicities in cancer patients undergoing EGFR inhibitor therapy. The trial is a critical step toward an Investigational New Drug (IND) submission to the FDA, leveraging Worldwide's expertise in clinical studies. Hoth's focus is on addressing significant unmet medical needs associated with cancer treatment.

Hoth Therapeutics, Inc. (Nasdaq: HOTH) announced that the Brazilian Patent Office granted a notice of allowance for a patent application concerning a method to inhibit biofilm formation, issued on March 31, 2021. This new patent, noted by CEO Robb Knie, is part of the company's strategy to broaden its intellectual property portfolio in underserved global markets. The method, discovered by University of Cincinnati researchers, utilizes a zinc chelator to prevent biofilm creation by bacteria such as Staphylococcus epidermidis and Staphylococcus aureus.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced positive in vitro results for its lead peptide candidate HT-002, aimed at treating COVID-19. The study demonstrated that HT-002 inhibited 50% of the cytopathic effect of SARS-CoV-2 at an effective concentration (EC₅₀) of 61.7 µM, with no observed cytotoxicity at concentrations up to 200 µM. Hoth plans further preclinical animal studies to explore the therapeutic potential and administration routes for HT-002, indicating a promising step in combating COVID-19.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced that CEO Robb Knie will present at the Benzinga Biotech Small Cap Conference on March 24, 2021, at 12:10 p.m. ET. Following this, he will join a panel discussion titled 'Coming Together to Address Unmet Medical Needs' at 12:50 p.m. ET.

Interested attendees can register for the webcast by visiting Benzinga's event page. Hoth Therapeutics focuses on developing therapies for dermatological disorders and has recently advanced vaccine projects for COVID-19.

Hoth Therapeutics, Inc. (Nasdaq: HOTH), a clinical-stage biopharmaceutical company, announced that CEO Robb Knie will feature in an exclusive interview on The RedChip Money Report airing on Bloomberg Television on March 20 at 7 p.m. ET. The segment, reaching 73 million homes in the U.S. and 100 million in Europe, will cover Hoth's focus on targeted therapeutics for unmet medical needs, highlighting its pipeline including the BioLexa Platform and HT-001.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) has entered into a research agreement with the University of Cincinnati Research Institute to conduct antimicrobial characterization studies for HT-006, a novel antibiotic targeting multi-drug resistant bacterial lung infections. The studies aim to expedite HT-006's development towards clinical use, addressing critical conditions like hospital-acquired pneumonia. Dr. Daniel Hassett will lead the research, which aligns with FDA guidelines for antibacterial therapies.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) has partnered with REPROCELL Ltd. to evaluate the HT-003 therapeutic platform's effects on ulcerative colitis and Crohn's disease tissues. This collaboration aims to characterize therapies for inflammatory bowel diseases, which affect around 3 million adults in the U.S. The active ingredient in HT-003 shows anti-inflammatory properties targeting retinoic acid metabolism. Hoth is working on multiple studies to meet unmet patient needs in various indications.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) has successfully closed a private placement, raising $15.0 million through the issuance of 7,594,937 shares of common stock at $1.975 each. The offering also includes warrants with an exercise price of $1.86 per share. Proceeds will be used for product development and general corporate purposes. Hoth's largest shareholder has extended a one-year lockup agreement, which may stabilize share prices. The company is required to file a registration statement for the resale of shares within 15 days.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced a definitive agreement for a private placement of 7,594,937 shares of common stock and warrants to purchase the same number of shares at $1.975 each, expected to yield approximately $15 million. The placement is set to close around March 10, 2021. The gross proceeds will fund the development of Hoth's product candidates and general corporate purposes. The warrants will have an exercise price of $1.86 and a three-year term.